File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Article: Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes
Title | Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes |
---|---|
Authors | |
Issue Date | 1-Nov-2024 |
Publisher | Alimentary Pharmacology & Therapeutics |
Citation | Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver-related mortality in patients with diabetes, 2024, v. 60, n. 10, p. 1398-1408 How to Cite? |
Abstract | Background: Optimal glycaemic control has well-established health benefits in patients with diabetes mellitus (DM). It is uncertain whether optimal glycaemic control can benefit liver-related outcomes. Aims: To examine the association of optimal glycaemic control with hepatocellular carcinoma (HCC) and liver-related mortality. Methods: In a population-based cohort, we identified patients with newly diagnosed DM between 2001 and 2016 in Hong Kong. Optimal glycaemic control was defined as mean haemoglobin A1c (HbA1c) <7% during the 3-year lead-in period after DM diagnosis. By applying propensity score matching to balance covariates, we analysed glycaemic control via competing risk models with outcomes of interest being HCC and liver-related mortality. Results: We identified 146,430 patients (52.2% males, mean age 61.4 ± 11.8 years). During a median follow-up duration of 7.0 years, 1099 (0.8%) and 978 (0.7%) patients developed HCC and liver-related deaths. Optimal glycaemic control, when compared to suboptimal glycaemic control, was associated with reduced risk of HCC (subdistribution hazard ratio [SHR] 0.70, 95% CI 0.61-0.79). The risk of HCC increased with incremental HbA1c increases beyond >7% (SHR 1.29-1.71). Significant associations with HCC were also found irrespective of age (SHR 0.54-0.80), sex (SHR 0.68-0.69), BMI <25 or ≥25 kg/m2 (SHR 0.63-0.75), smoking (SHR 0.61-0.72), hepatic steatosis (SHR 0.67-0.68) and aspirin/statin/metformin use (SHR 0.67-0.75). A lower risk of liver-related mortality in relation to optimal glycaemic control was also observed (SHR 0.70, 95% CI 0.61-0.80). Conclusions: Glycaemic control is an independent risk factor for HCC and liver-related mortality, and should be incorporated into oncoprotective strategies in the general DM population. |
Persistent Identifier | http://hdl.handle.net/10722/350827 |
ISSN | 2023 Impact Factor: 6.6 2023 SCImago Journal Rankings: 2.794 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mao, Xianhua | - |
dc.contributor.author | Cheung, Ka-Shing | - |
dc.contributor.author | Tan, Jing-Tong | - |
dc.contributor.author | Mak, Lung-Yi | - |
dc.contributor.author | Lee, Chi-Ho | - |
dc.contributor.author | Chiang, Chi-Leung | - |
dc.contributor.author | Cheng, Ho-Ming | - |
dc.contributor.author | Hui, Rex Wan-Hin | - |
dc.contributor.author | Leung, Wai K | - |
dc.contributor.author | Yuen, Man-Fung | - |
dc.contributor.author | Seto, Wai-Kay | - |
dc.date.accessioned | 2024-11-03T00:30:39Z | - |
dc.date.available | 2024-11-03T00:30:39Z | - |
dc.date.issued | 2024-11-01 | - |
dc.identifier.citation | Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver-related mortality in patients with diabetes, 2024, v. 60, n. 10, p. 1398-1408 | - |
dc.identifier.issn | 0269-2813 | - |
dc.identifier.uri | http://hdl.handle.net/10722/350827 | - |
dc.description.abstract | <p><strong>Background: </strong>Optimal glycaemic control has well-established health benefits in patients with diabetes mellitus (DM). It is uncertain whether optimal glycaemic control can benefit liver-related outcomes.</p><p><strong>Aims: </strong>To examine the association of optimal glycaemic control with hepatocellular carcinoma (HCC) and liver-related mortality.</p><p><strong>Methods: </strong>In a population-based cohort, we identified patients with newly diagnosed DM between 2001 and 2016 in Hong Kong. Optimal glycaemic control was defined as mean haemoglobin A1c (HbA1c) <7% during the 3-year lead-in period after DM diagnosis. By applying propensity score matching to balance covariates, we analysed glycaemic control via competing risk models with outcomes of interest being HCC and liver-related mortality.</p><p><strong>Results: </strong>We identified 146,430 patients (52.2% males, mean age 61.4 ± 11.8 years). During a median follow-up duration of 7.0 years, 1099 (0.8%) and 978 (0.7%) patients developed HCC and liver-related deaths. Optimal glycaemic control, when compared to suboptimal glycaemic control, was associated with reduced risk of HCC (subdistribution hazard ratio [SHR] 0.70, 95% CI 0.61-0.79). The risk of HCC increased with incremental HbA1c increases beyond >7% (SHR 1.29-1.71). Significant associations with HCC were also found irrespective of age (SHR 0.54-0.80), sex (SHR 0.68-0.69), BMI <25 or ≥25 kg/m<sup>2</sup> (SHR 0.63-0.75), smoking (SHR 0.61-0.72), hepatic steatosis (SHR 0.67-0.68) and aspirin/statin/metformin use (SHR 0.67-0.75). A lower risk of liver-related mortality in relation to optimal glycaemic control was also observed (SHR 0.70, 95% CI 0.61-0.80).</p><p><strong>Conclusions: </strong>Glycaemic control is an independent risk factor for HCC and liver-related mortality, and should be incorporated into oncoprotective strategies in the general DM population.</p> | - |
dc.language | eng | - |
dc.publisher | Alimentary Pharmacology & Therapeutics | - |
dc.relation.ispartof | Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver-related mortality in patients with diabetes | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes | - |
dc.type | Article | - |
dc.identifier.doi | 10.1111/apt.18254 | - |
dc.identifier.volume | 60 | - |
dc.identifier.issue | 10 | - |
dc.identifier.spage | 1398 | - |
dc.identifier.epage | 1408 | - |
dc.identifier.eissn | 1365-2036 | - |
dc.identifier.issnl | 0269-2813 | - |